Pharmerging Market Report 2026

The pharmerging market size has grown rapidly in recent years. It will grow from $2.25 trillion in 2025 to $2.49 trillion in 2026 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to increasing healthcare spending in emerging economies, expansion of generic drug availability, rising burden of infectious and lifestyle diseases, growth of local pharmaceutical manufacturing, improved healthcare infrastructure access.

The pharmerging market size is expected to see rapid growth in the next few years. It will grow to $3.67 trillion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing penetration of specialty medicines in pharmerging regions, rising investments in regional R&D centers, expansion of digital distribution channels, growing demand for chronic disease treatments, increasing regulatory harmonization across emerging markets. Major trends in the forecast period include increasing expansion of pharmaceutical operations in emerging markets, rising localization of drug manufacturing, growing focus on affordable healthcare solutions, expansion of generic and biosimilar portfolios, enhanced emphasis on market-specific product strategies.

The rising healthcare expenditure is expected to drive the growth of the pharmerging market in the coming years. Healthcare expenditure refers to the total funds allocated to medical services, treatments, facilities, research, and public health initiatives aimed at maintaining or improving health outcomes. The growing need for healthcare expenditure is largely due to the aging population, which demands more medical care, treatments, and long-term healthcare services. Increased healthcare expenditure fuels the growth of pharmerging by enhancing access to medical services, supporting infrastructure development, and promoting wider adoption of affordable medicines. For example, in December 2024, the US federal agency, Centers for Medicare & Medicaid Services (CMS), reported that national health expenditures (NHE) increased by 7.5% in 2023, reaching $4.9 trillion and representing 17.6% of GDP. Looking ahead, NHE is expected to grow at an average annual rate of 5.6% from 2023 to 2032, with the health spending share of GDP rising from 17.3% in 2022 to 19.7% by 2032. Therefore, the rising healthcare expenditure is propelling the growth of the pharmerging market.

The rising burden of chronic disease expenditure is expected to drive the growth of the emerging market in the coming years. Chronic diseases are long-lasting medical conditions, typically persisting for three months or more, and often progress gradually over time. The rising prevalence of chronic diseases is mainly attributed to an aging population, as older adults are more vulnerable to long-term conditions such as diabetes, heart disease, and arthritis. Pharmerging markets are addressing chronic diseases by improving access to affordable medications, innovative therapies, and healthcare infrastructure in regions experiencing increasing disease prevalence. For example, in April 2025, according to the NHS Confederation, a UK-based national association, it is projected that by 2035, 17% of the UK population could be living with four or more chronic conditions. Thus, the rising prevalence of chronic diseases is fueling the growth of the pharmerging market.

Major companies operating in the pharmerging market are emphasizing the development of innovative solutions, such as combination drug therapies, to address complex medical conditions and enhance treatment outcomes. Combination drug therapies involve the use of two or more active drugs together in a single regimen to improve efficacy and target multiple facets of a medical condition simultaneously. For example, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based contract development and manufacturing organization, introduced Rabeprazole + Levosulpiride SR capsules, a newly approved formulation by the Drug Controller General of India (DCGI) aimed at treating gastroesophageal reflux disease (GERD) and other gastrointestinal disorders. These capsules combine Rabeprazole, a proton pump inhibitor that reduces stomach acid production, with Levosulpiride, a prokinetic agent that enhances stomach and intestinal motility to prevent acid reflux. This dual action provides comprehensive relief from GERD symptoms by simultaneously decreasing acid secretion and improving gastrointestinal function.

Major companies operating in the pharmerging market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, GE Healthcare Technologies Inc., Alembic Ltd., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Limited, Lupin Limited, Beximco Pharmaceuticals Ltd.

North America was the largest region in the pharmerging market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmerging market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmerging market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the pharmerging market by increasing costs of imported active pharmaceutical ingredients, manufacturing equipment, packaging materials, and medical devices required for market expansion. Emerging regions in Asia-Pacific, Latin America, and Africa are most affected due to dependence on cross-border supply chains, while multinational firms face margin pressure on localized production. These tariffs are impacting drug pricing and supply consistency. However, they are also encouraging domestic manufacturing, regional API production, and stronger local supply chains that support long-term market resilience.

The pharmerging market research report is one of a series of new reports that provides pharmerging market statistics, including pharmerging industry global market size, regional shares, competitors with a pharmerging market share, detailed pharmerging market segments, market trends and opportunities, and any further data you may need to thrive in the pharmerging industry. This pharmerging market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmerging refers to the approach of pharmaceutical companies entering emerging markets to stimulate growth and reach new patient groups. It emphasizes seizing opportunities in countries with quickly developing healthcare systems and rising demand for medications.

The primary product categories of pharmerging include pharmaceuticals, medical devices, diagnostics, biotechnology, and generics. Pharmaceuticals are substances or products utilized in the diagnosis, treatment, prevention, or management of diseases and medical conditions. They are used for various indications such as lifestyle diseases, cancer and autoimmune diseases, infectious diseases, and others, and are available in different formulations including solid oral, liquid oral, injectable, topical, and others. They have applications across therapeutic, diagnostic, preventive, and research and development areas, and are distributed through hospitals and clinics, retail pharmacies, online marketplaces, wholesale distributors, and direct-to-consumer channels.

The pharmerging market consists of revenues earned by entities by providing services such as contract research and manufacturing services (CRAMS), diagnostic testing and healthcare services, distribution and retail pharmacy operations, and the supply of medical devices and equipment. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmerging market also includes sales of over-the-counter (OTC) medicines, vaccines, biologics and biosimilars, and personal care and wellness products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.